Overview

• Fresenius posted a 7% increase in Q1 revenue to €5.63 billion, with EBIT up 4% to €654 million and net profit rising 12% to €416 million.
• The company attributes its financial success to cost-saving measures and strong performance in its Kabi division, which focuses on generics, clinical nutrition, and medical technology.
• Fresenius is in active discussions with US regulators to maintain the pharmaceutical import tariff exemption, as its review could impact global suppliers.
• Kabi produces 70% of its US-sold medications locally, insulating Fresenius from potential tariffs and strengthening its position in the American market.
• Despite tariff uncertainties, Fresenius has reaffirmed its 2025 revenue growth target of 4–6%, factoring in identifiable risks.